StockData
Evaxion A/S logo

Evaxion A/S (EVAX) stock

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.54−0.24 (-8.63%)

Close on Nov 18, 2026Market cap $21.18MP/E –Yield –

Evaxion A/S free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Evaxion A/S's free cash flow for the twelve months ending Jun 30, 2022 was -$24.56M. For fiscal 2025 it was -$6.64M. The highest annual figure on record is -$2.00M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.64M–
FY2024Dec 31, 2024-$12.94M–
FY2023Dec 31, 2023-$17.78M–
FY2022Dec 31, 2022-$26.07M–
FY2021Dec 31, 2021-$23.23M–
FY2020Dec 31, 2020-$12.59M–
FY2019Dec 31, 2019-$7.08M–
FY2018Dec 31, 2018-$2.00M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022-$5.27M–
Q1 FY2022Mar 31, 2022-$8.37M–
Q4 FY2021Dec 31, 2021-$4.29M–
Q3 FY2021Sep 30, 2021-$6.63M–
Q2 FY2021Jun 30, 2021-$8.00M–
Q1 FY2021Mar 31, 2021-$4.32M–
Q4 FY2020Dec 31, 2020-$4.49M–
Q3 FY2020Sep 30, 2020-$2.77M–
Q2 FY2020Jun 30, 2020-$2.31M–
Q1 FY2020Mar 31, 2020-$3.01M–

More Evaxion A/S figures

See a number that looks wrong?